Hope Rugo, MD | Authors

Hope S. Rugo, MD, on Comparing CDK4/6 Inhibitors in HR+/HER2– Advanced Breast Cancer

July 24, 2022

Hope S. Rugo, MD, FASCO, reviewed data from a matching-adjusted indirect comparison study which analyzed quality of life in patients with hormone receptor–positive, HER2-negative advanced breast cancer treated with ribociclib- or abemaciclib-based regimens.

Hope S. Rugo, MD, FASCO, Reviews TROPiCS-02 Trial Data in HR+/HER2– Advanced Breast Cancer at 2022 ASCO

June 09, 2022

Hope S. Rugo, MD, spoke about results of the phase 3 TROPiCS-02 trial examining sacituzumab govitecan vs physicians’ choice chemotherapy for patients with hormone receptor–positive, HER2-negative advanced breast cancer presented at ASCO 2022.